Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Thursday, May 01, 2014 9:43:41 AM
Here is a Reason to be Optimistic about the Upcoming Phase 3 Results in June
.
Maybe this is the reason why Insider Holding a large Position in this undiscovered Goldmine and maybe why the new great Directors coming to Adherex . If Final Phase 3 results is positive then this Low Float Monster will explode like a Nuclear Bomb because the Drug has Orphan drug Status and it will be the only Drug for this Indication on the Market for a Long time because no Competitors out there . GLTA
---------
Adherex Announces Sodium Thiosulfate Clinical Study Update
~ Data have been submitted to ASCO 2014~
Adherex’s collaborator the Children’s Oncology Group (COG) posted top-line results from a Phase III trial of Adherex’s lead candidate STS to clinicaltrials.gov last week. The data are incomplete and no statistical analysis was performed. A full analysis of secondary endpoints such as event free survival and overall survival was not posted. Any interpretation should be limited until Adherex reports the full data, which is expected at the American Society of Clinical Oncology (ASCO) meeting in June 2014.
Posted Data, though Incomplete, is Encouraging. According to the posted results, the data regarding the frequency of patients with hearing loss is encouraging, and may support the primary endpoint after a full statistical analysis. The primary endpoint of the trial is hearing protection in pediatric oncology patients undergoing platinum-based chemotherapy.
The posted data show that out of 56 patients in the cisplatin arm of the study, 31 (55%) experienced hearing loss. For the 49 patients treated with STS and cisplatin, 14 (29%) experienced hearing loss. Information posted on the website is incomplete and final results may differ from those presented.
Adherex has announced that COG has already submitted an abstract for presentation at 2014 American Society of Clinical Oncology Meeting. The Company indicated that no other study data is available for public disclosure at this time.
Recent FENC News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/05/2024 09:02:25 PM
- Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 09/05/2024 10:56:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:48:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 10:33:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/04/2024 08:05:38 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 08/27/2024 09:30:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2024 09:51:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:02:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 11:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/19/2024 10:59:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 09:10:11 PM
- Fennec Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 10:05:00 AM
- Fennec Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:31:00 PM
- Fennec Pharmaceuticals Appoints Jeffrey S. Hackman as Chief Executive Officer and Director • GlobeNewswire Inc. • 08/05/2024 10:26:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:30:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:21:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:08:11 PM
- Fennec Pharmaceuticals Announces Management Change • GlobeNewswire Inc. • 07/01/2024 10:00:00 AM
- Fennec Announces Results of Annual Meeting • GlobeNewswire Inc. • 06/25/2024 08:35:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 10:21:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/03/2024 09:12:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:29:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 09:05:25 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM